Document:

THIS WARRANT AND ANY SECURITIES ACQUIRED
UPON THE EXERCISE OF THIS WARRANT HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES
LAWS AND MAY NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT
TO THE SECURITIES EVIDENCED BY THIS CERTIFICATE, FILED AND MADE EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND SUCH
APPLICABLE STATE SECURITIES LAWS, OR UNLESS SOLD PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS PROVIDED THAT THE
COMPANY RECEIVES AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER SUCH ACT AND SUCH APPLICABLE
STATE SECURITIES LAWS IS NOT REQUIRED.

 

	Warrant Certificate No. 2014-__	Dated: _______, 2014

 

WARRANT

 

Enumeral Biomedical
Corp.

 

Expiring: _______, 2024

 

THIS IS TO CERTIFY THAT, for value received,
_____________________ (the “Holder”), is entitled, subject to certain conditions set forth in Sections 1.01
and 1.02 hereof, to purchase from Enumeral Biomedical Corp., a Delaware corporation (the “Company”), at the Company’s
principal executive office, at a price per share of $0.27 (the “Exercise Price”), up to _______ shares (the “Warrant
Shares”) of the Company’s Common Stock, $0.0001 par value per share (“Common Stock”), all subject to adjustment
and upon the terms and conditions as hereinafter provided, and is entitled also to exercise the other appurtenant rights, powers
and privileges hereinafter described.

 

Certain terms used in this Warrant are defined
in Article IV hereof.

 

Article
I.

 

METHOD
OF EXERCISE

 

Section 1.01         Time
of Exercise. Subject to the provisions of Sections 1.02 and 1.03 hereof, this Warrant may be exercised in whole or in part
at any time and from time to time prior to the Expiration Time.

 

Section 1.02         Method of Exercise.

 

		(a)	To exercise this Warrant in whole or in part, the Holder shall deliver to the Company, at the Company’s principal executive
office (a) this Warrant, (b) a written notice of such Holder’s election to exercise this Warrant in the form attached hereto
as Exhibit A and (c) payment of an amount equal to the Exercise Price multiplied by the total number of Warrant Shares for
which this Warrant is then being exercised. Such payment may be made, at the option of the Holder, in cash, by certified or bank
cashier’s check, money order or wire transfer, or any combination thereof, or in any other manner consented to in writing
by the Company.

 

    	 

    	 

    

 

		(b)	In lieu of cash exercising this Warrant in accordance with (a) above, at any time from and after a Deemed Liquidation Event
(as defined in the Company Certificate), the Holder may elect to receive shares equal to the value of this Warrant (or the portion
thereof being canceled) by surrender of this Warrant to the Company together with notice of such election, in which event the Company
shall issue to the Holder hereof a number of Shares computed using the following formula:

 

Y (A-B)

X=          A

 

Where:

 

X equals the number of Warrant Shares
to be issued to the Holder;

 

Y equals the number of Warrant Shares
purchasable under the Warrant, or, if only a portion of the Warrant is being exercised, the portion of the Warrant being exercised
at the date of such calculation;

 

A equals the Fair Market Value of one
Warrant Share (at the date of such calculation); and

 

B equals the Exercise Price (as adjusted
to the date of such calculations).

 

		(c)	The Company shall, as promptly as practicable after receipt of the items required by this Section 1.02, execute and deliver
or cause to be executed and delivered, in accordance with such notice, a certificate or certificates representing the Warrant Shares
specified in such notice. The share certificate or certificates so delivered shall be in such denominations as shall be specified
in such notice and shall be issued in the name of the Holder or, provided, in an opinion of counsel reasonably acceptable to the
Company, the following is permitted under the Act and applicable state securities law, such other name as shall be designated in
such notice. Such certificate or certificates shall be deemed to have been issued, and such Holder or Holders or any other person
so designated to be named therein shall be deemed for all purposes to have become a Holder of record of such shares as of the date
the aforementioned notice is received by the Company. If this Warrant shall have been exercised only in part, the Company shall,
at the time of delivery of the certificate or certificates, deliver to the Holder a new Warrant evidencing the right to purchase
the remaining Warrant Shares called for by this Warrant, which new Warrant shall in all other respects be identical to this Warrant,
or, at the request of the Holder, appropriate notations may be made on this Warrant which shall then be returned to the Holder.
The Company shall pay all expenses, taxes and other charges payable in connection with the preparation, issuance and delivery of
share certificates and new Warrants, except that, if share certificates or new Warrants shall be registered in a name or names
other than the name of the Holder, funds sufficient to pay all transfer taxes, if any, payable as a result of such transfer shall
be paid by the Holder at the time of delivering the aforementioned notice of exercise or promptly upon receipt of a written request
of the Company for payment.

 

    	2

    	 

    

 

Section 1.03         Shares
To Be Fully Paid and Nonassessable. All shares of Common Stock issued upon exercise of the Warrant shall be validly issued,
fully paid and nonassessable.

 

Section 1.04         No
Fractional Shares To Be Issued. The Company shall not be required to issue fractions of Warrant Shares upon exercise of this
Warrant. If any fractions of a share would, but for this Section, be issuable upon any exercise of this Warrant, in lieu of such
fractional share the Company shall pay to the Holder, in cash, an amount equal to the same fraction of the fair market value of
one share of Common Stock.

 

Section 1.05         Share
Legend. Each certificate for Warrant Shares issued upon exercise of this Warrant, unless at the time of exercise such shares
are registered under the Act, shall bear a legend substantially as follows or similar legend as determined in good faith by the
Company’s Board of Directors:

 

THE SECURITIES REPRESENTED BY THIS
CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS AND MAY
NOT BE TRANSFERRED, SOLD OR OTHERWISE DISPOSED OF IN THE ABSENCE OF AN EFFECTIVE REGISTRATION STATEMENT WITH RESPECT TO THE SECURITIES
EVIDENCED BY THIS CERTIFICATE, FILED AND MADE EFFECTIVE UNDER THE SECURITIES ACT OF 1933, AS AMENDED, AND SUCH APPLICABLE STATE
SECURITIES LAWS, OR UNLESS SOLD PURSUANT TO AN EXEMPTION FROM SUCH REGISTRATION REQUIREMENTS PROVIDED THAT THE COMPANY RECEIVES
AN OPINION OF COUNSEL SATISFACTORY TO THE COMPANY TO THE EFFECT THAT REGISTRATION UNDER SUCH ACT AND SUCH APPLICABLE STATE SECURITIES
LAWS IS NOT REQUIRED.

 

Any certificate issued at any time in exchange
or substitution for any certificate bearing such legend (except a new certificate issued upon completion of a public distribution
pursuant to a registration statement under the Act) shall also bear such legend unless, in the opinion of counsel reasonably acceptable
to the Company, the securities represented thereby no longer need to be subject to restrictions on resale under the Act.

 

Section 1.06         Reservation
of Stock. The Company agrees during the term the rights under this Warrant are exercisable to reserve and keep available from
its authorized and unissued shares of Common Stock for the purpose of effecting the exercise of this Warrant such number of shares
of Common Stock (and shares of the Company’s Common Stock for issuance upon conversion of such Warrant Shares) as shall from
time to time be sufficient to effect the exercise of the rights under this Warrant.

 

    	3

    	 

    

 

Section 1.07         Transfers.
Neither this Warrant nor any rights hereunder may be assigned, conveyed or transferred, in whole or in part, without the Company’s
prior written consent, which the Company may withhold in its sole discretion; provided, however, that this Warrant
: (a) may be pledged without the prior written consent of the Company to any lender to the Holder as part of a bona fide secured
loan or credit facility (and, following a default thereunder, this Note may be transferred to such lender without the Company’s
consent), and (b) may be assigned, conveyed or transferred without the prior written consent of the Company to any Affiliate of
the Holder; provided, further, that Holder surrenders this Warrant properly endorsed or accompanied by written instructions
of transfer in the form of attached hereto as Exhibit B, and any such permitted transferee executes an acknowledgement that
such transferee is subject to all the terms and conditions of this Warrant and satisfies the Company as to compliance with state
and federal securities law.

 

Article
II.

 

WARRANT
ADJUSTMENTS

 

Section 2.01         Merger.
If at any time there shall be a merger, acquisition or consolidation of the Company with or into another corporation, where the
Company is not the surviving corporation, or a sale of all or substantially all of the Company’s assets, then, as a part
of such merger or consolidation, lawful provision shall be made so that the Holder shall thereafter be entitled to receive upon
exercise of this Warrant, during the period specified herein and upon payment of the aggregate Exercise Price then in effect, the
number of shares of stock or other securities, cash or other property of the successor corporation resulting from such merger or
consolidation, to which a holder of the stock deliverable upon exercise of this Warrant would have been entitled in such merger
or consolidation if this Warrant had been exercised immediately before such merger or consolidation. In any such case, appropriate
adjustment shall be made in the application of the provisions of this Warrant with respect to the rights and interests of the Holder
after the merger or consolidation.

 

Section 2.02         Reclassification,
etc. If the securities issuable upon exercise of this Warrant are changed into the same or a different number of securities
of any other class or classes by reclassification, capital reorganization, conversion of all outstanding shares of the relevant
class or series or otherwise (other than as otherwise provided for herein) (a “Reclassification”), then, in any such
event, in lieu of the number of Warrant Shares which the Holder would otherwise have been entitled to receive, the Holder shall
have the right thereafter to exercise this Warrant for a number of shares of such other class or classes of stock that a holder
of the number of securities deliverable upon exercise of this Warrant immediately before that change would have been entitled to
receive in such Reclassification, all subject to further adjustment as provided herein with respect to such other shares.

 

    	4

    	 

    

 

Section 2.03         Split,
Subdivision or Combination of Shares. If the Company at any time while this Warrant remains outstanding and unexpired shall
split, subdivide or combine its Common Stock, the Exercise Price shall be proportionately decreased and the number of Warrant Shares
purchasable hereunder shall be proportionately increased in the case of a split, payment of a stock dividend (of shares of Common
Stock) or subdivision, or the Exercise Price shall be proportionately increased and the number of shares of Warrant Shares purchasable
hereunder shall be proportionately decreased in the case of a combination.

 

Section 2.04         Notice
of Adjustments; Notices. Whenever the Exercise Price or number of Warrant Shares issuable upon exercise hereof shall be adjusted
pursuant to Article II hereof, the Company shall issue a written notice setting forth, in reasonable detail, the event requiring
the adjustment, the amount of the adjustment, the method by which such adjustment was calculated and the Exercise Price and number
of Warrant Shares purchasable hereunder after giving effect to such adjustment, and shall cause a copy of such notice to be given
in accordance with Article VI hereof.

 

Article
III.

 

REPLACEMENTS
OF WARRANT CERTIFICATES

 

Section 3.01         Loss,
Theft or Destruction of Warrant Certificates. Upon receipt of evidence satisfactory to the Company of the loss, theft, destruction
or mutilation of any Warrant and, in the case of any such loss, theft or destruction, upon receipt of indemnity or security from
the Holder satisfactory to the Company, or, in the case of any such mutilation, upon surrender and cancellation of the Warrant,
the Company will make and deliver, in lieu of such lost, stolen, destroyed or mutilated Warrant, a new Warrant of like tenor and
representing the right to purchase the same aggregate number of Warrant Shares.

 

Section 3.02         Change
of Principal Executive Office. In the event the Company shall change the address of its principal executive office, the Company
shall give the Holder notice of any such change within a reasonable time. Any correspondence from the Company to the Holder with
an address printed on Company’s letterhead shall fulfill this requirement.

 

Article
IV.

 

DEFINITIONS

 

The following terms, as used in this Warrant,
have the following respective meanings:

 

“Act” means the Securities Act of
1933, as amended, and any similar or successor federal statute, and the rules and regulations of the Securities and Exchange Commission
(or its successor) thereunder, all as the same shall be in effect at the time.

 

“Affiliate” means, with respect to
the Holder, any other person who, directly or indirectly, controls, is controlled by, or is under common control with such Holder,
including, without limitation, any general partner, managing member, officer or director of such Holder or any venture capital
fund now or hereafter existing that is controlled by one or more general partners or managing members of, or shares the same management
company with, such Holder.

 

    	5

    	 

    

 

“Common Stock” means the Company’s
common stock, $0.0001 per share.

 

“Company” shall have the meaning set
forth in the first paragraph of this Warrant.

 

“Company Certificate” means the Third
Amended and Restated Certificate of Incorporation of the Company, as amended from time to time.

 

“Eastern Time” means Eastern Daylight
Time or Eastern Standard Time, whichever is in effect on the relevant date.

 

“Expiration Time” means 5:00 p.m.
Eastern Time on February 2, 2024.

 

“Fair Market Value” shall mean the
aggregate consideration payable on account of one share of Common Stock as a result of the Deemed Liquidation Event (as defined
in the Company Certificate) giving rise to the Holder’s rights under Section 1.02(b).

 

“Holder” shall have the meaning set
forth in the first paragraph of this Warrant and “Holders” shall include any and all successors and assigns of the
initial Holder with respect to this Warrant.

 

“Warrant” and “Warrants”
shall mean this warrant and any warrants issued upon the partial exercise of this warrant.

 

Article
V.

 

REDEMPTION
AND CANCELLATION OF WARRANTS

 

Section 5.01         Redemption
of Warrants. The Warrants are not redeemable by the Company and the Company has no right to purchase or otherwise acquire the
Warrants.

 

Section 5.02         Cancellation
of Warrants. The Company shall cancel any Warrant surrendered for transfer, exchange or exercise.

 

Article
VI.

 

MISCELLANEOUS

 

Section 6.01         Notices.
Except with respect to notice of a change in the Company’s principal executive office in accordance with Section 3.02 hereof,
all notices, requests and other communications provided for herein shall be in writing, and shall be deemed duly given if delivered
personally or mailed by registered or certified mail (return receipt requested) or via overnight courier to the parties at the
following addresses (or at such other address for such party as shall be specified by written notice):

 

	(a)          If
to the Company:		Enumeral Technologies, Inc.

1450 Broadway, 24th Floor

New York, NY 10018

Attn: Arthur Tinkelenberg

 

    	6

    	 

    

 

		with a copy to:	Duane Morris LLP

100 High Street, 24th Floor

Boston, MA 02110

Attention:      Jonathan Lourie, Esq.

Telephone:    857-488-4260

Facsimile:       857-401-3089

 

	(b)          If
to the Holder:		____________________________

 

Section 6.02         Waivers;
Amendments. No failure or delay of the Holder in exercising any right, power or privilege, hereunder shall operate as a waiver
thereof, nor shall any single or partial exercise thereof, or any abandonment or discontinuance of steps to enforce such a right,
power or privilege, preclude any other or further exercise thereof or the exercise of any other right, power or privilege. The
rights and remedies of the Holder are cumulative and not exclusive of any rights or remedies which it would otherwise have. The
provisions of this Warrant may be amended, modified or waived if, but only if, such amendment, modification or waiver is in writing
and is signed by the Holder.

 

Section 6.03         Governing
Law. This Warrant shall be construed in accordance with and governed by the laws of the State of Delaware, without regard to
the conflict of laws rules thereof to the extent that the application of the law of another jurisdiction would be required thereby.

 

Section 6.04         Survival
of Agreements; Representations and Warranties, etc. All warranties, representations and covenants made by the Company herein
or in any certificate or other instrument delivered by or on behalf of it in connection herewith shall be considered to have been
relied upon by the Holder and shall survive the issuance and delivery of the Warrants and shall continue in full force and effect
so long as this Warrant is outstanding. All statements in any such certificate or other instrument shall constitute representations
and warranties hereunder.

 

Section 6.05         Covenants
To Bind Successor and Assigns. All the covenants, stipulations, promises and agreements in this Warrant contained by or on
behalf of the Company shall bind its successors and assigns, whether or not so expressed.

 

Section 6.06         Severability.
In case any one or more of the provisions contained in this Warrant shall be invalid, illegal or unenforceable in any jurisdiction,
the validity, legality and enforceability of the remaining provisions contained herein and therein shall not in any way be affected
or impaired in such jurisdiction and shall not invalidate or render illegal or unenforceable such provision in any other jurisdiction.

 

    	7

    	 

    

 

Section 6.07         Headings.
The headings used herein are for convenience of reference only and shall not be deemed to be a part of this Warrant.

 

Section 6.08         No
Rights as Stockholder. This Warrant shall not entitle the Holder to any rights as a stockholder of the Company.

 

Section 6.09         No
Impairment. The Company shall not, by amendment of the Company Certificate or through a reorganization, transfer of assets,
consolidation, merger, dissolution, issue, or sale of securities or any other voluntary action, avoid or seek to avoid the observance
or performance of any of the terms to be observed or performed under this Warrant by the Company, but shall at all times in good
faith assist in carrying out of all the provisions of this Warrant and in taking all such action as may be necessary or appropriate
to protect the Holder’s rights under this Warrant against impairment.

 

Section 6.10         Pronouns.
The pronouns “it” and “its” herein shall be deemed to mean “he” and “his” or “she”
and “hers,” as the context requires.

 

[The remainder of this page intentionally left
blank – signature page follows]

    	8

    	 

    

 

IN WITNESS WHEREOF, Enumeral Biomedical Corp.
has caused this Warrant to be executed in its corporate name by one of its officers thereunto duly authorized as of the day and
year first above written.

 

	 	ENUMERAL BIOMEDICAL CORP.
	 	 
	 	By: 	 
	 	 	Name: 	Arthur Tinkelenberg
	 	 	Title:	President and CEO

 

    	9

    	 

    

 

EXHIBIT A

 

FORM OF NOTICE
OF EXERCISE

 

[To be signed only upon exercise of the Warrant]

 

		TO:	Enumeral Biomedical Corp.

 

1.          The
undersigned hereby elects to purchase __________ shares of _____________ pursuant to the terms of the attached Warrant.

 

2.          Method
of Exercise (Please initial the applicable blank):

 

		___	The undersigned elects to exercise the attached Warrant by means of a cash payment, and tenders
herewith payment in full for the purchase price of the shares being purchased, together with all applicable transfer taxes, if
any.

 

		___	The undersigned elects to exercise the attached Warrant by means of the net exercise provisions
of Section 1.02(b) of the Warrant.

 

3.          Please
issue a certificate or certificates representing said Shares in the name of the undersigned or in such other name as is specified
below:

 

	 	 	 
	 	(Name)	 
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	 	(Address)	 

 

4.          The
undersigned hereby represents and warrants that the aforesaid Shares are being acquired for the account of the undersigned for
investment and not with a view to, or for resale, in connection with the distribution thereof, and that the undersigned has no
present intention of distributing or reselling such shares.

 

	 	 	 
	 	 	(Signature)
	 	 	 
	 	 	 
	 	 	(Name)
	 	 	 
	 	 	 
	(Date)	 	(Title)

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF TRANSFER

(To be signed only upon transfer of Warrant)

 

FOR VALUE RECEIVED, the
undersigned hereby sells, assigns and transfers unto _______________________________________________ the right represented by the
attached Warrant to purchase ____________ shares of Common Stock of Enumeral Biomedical Corp. to which the attached Warrant relates,
and appoints ______________ Attorney to transfer such right on the books of __________, with full power of substitution in the
premises.

 

Dated: ____________________

 

	 	 	 
	 	 	(Signature must conform in all respects to name of Holder as specified on the face of the Warrant)
	 	 	 
	 	 	Address: 	 
	 	 	 	 
	 	 	 	 

 

	Signed in the presence of:NCI Control Number: N43CO-2012-00073

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

    	 

    	 

    

 

 

    	 

    	 

    

 

Contract Number : HHSN261201200073C

NCI Control Number : N43CO-2012-00073

 

TABLE OF CONTENTS

 

	PART I - THE SCHEDULE	4
	SECTION B - SUPPLIES OR SERVICES AND PRICES/COSTS	4
	ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES	4
	ARTICLE B.2. PRICES	4
	ARTICLE B.3. ADVANCE UNDERSTANDINGS	4
	SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	6
	ARTICLE C.1. STATEMENT OF WORK	6
	ARTICLE C.2. REPORTING REQUIREMENTS	6
	ARTICLE C.3. INVENTION REPORTING REQUIREMENT	9
	SECTION D - PACKAGING, MARKING AND SHIPPING	11
	SECTION E - INSPECTION AND ACCEPTANCE	11
	SECTION F - DELIVERIES OR PERFORMANCE	12
	ARTICLE F.1. PERIOD OF PERFORMANCE	12
	ARTICLE F.2. DELIVERIES	12
	ARTICLE F.3. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)	13
	SECTION G - CONTRACT ADMINISTRATION DATA	14
	ARTICLE G.1. CONTRACTING OFFICER’S REPRESENTATIVE (COR)	14
	ARTICLE G.2. KEY PERSONNEL, HHSAR 352.242-70 (January 2006)	14
	ARTICLE G.3. INVOICE SUBMISSION	14
	ARTICLE G.4. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE	17
	SECTION H - SPECIAL CONTRACT REQUIREMENTS	18
	ARTICLE H.1. HUMAN SUBJECTS	18
	ARTICLE H.2. HUMAN MATERIALS	18
	ARTICLE H.3. HUMAN MATERIALS (ASSURANCE OF OHRP COMPLIANCE)	18
	ARTICLE H.4. NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH	18
	ARTICLE H.5. NEEDLE DISTRIBUTION	19
	ARTICLE H.6. ACKNOWLEDGEMENT OF FEDERAL FUNDING	19
	ARTICLE H.7. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH	19
	ARTICLE H.8. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION	19
	ARTICLE H.9. LIMITATIONS ON SUBCONTRACTING - SBIR	19
	ARTICLE H.10. ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY, HHSAR 352.239-73(b) (January 2010)	19
	ARTICLE H.11. PUBLICATION AND PUBLICITY	20
	ARTICLE H.12. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE	20
	ARTICLE H.13. YEAR 2000 COMPLIANCE	20
	PART II - CONTRACT CLAUSES	21
	SECTION I - CONTRACT CLAUSES	21
	ARTICLE I.1. GENERAL CLAUSES FOR A FIXED-PRICE RESEARCH AND DEVELOPMENT SBIR PHASE I CONTRACT	21
	ARTICLE I.2. AUTHORIZED SUBSTITUTION OF CLAUSES	23
	ARTICLE I.3. Additional Contract Clauses	24
	ARTICLE I.4. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT	25
	PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS	26
	SECTION J - LIST OF ATTACHMENTS	26
	1.  Statement of Work	26
	2.  Invoice Instructions for NIH Fixed-Price Contracts, NIH(RC)-2	26
	3.  Safety and Health	26
	4.  Disclosure of Lobbying Activities, SF-LLL	26

 

    	- 2 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

	PART IV - REPRESENTATIONS AND INSTRUCTIONS	27
	SECTION K - REPRESENTATIONS AND CERTIFICATIONS	27
	1.  Annual Representations and Certifications	27
	2.  Annual Representations and Certifications, FAR Clause 52.204-8	27

 

FOIA CONFIDENTIAL TREATMENT REQUESTED BY
ENUMERAL BIOMEDICAL HOLDINGS, INC.

 

    	- 3 -

    	 

    

 

Contract Number : HHSN261201200073C

NCI Control Number : N43CO-2012-00073

 

PART I - THE
SCHEDULE

 

SECTION
B - SUPPLIES OR SERVICES AND PRICES/COSTS

 

ARTICLE B.1.
BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

 

The goal of this project is to characterize Enumeral’s technology
for the * on clinical samples and to * for an * to be used in Phase II. Enumeral’s platform is ideally suited for the measurement
of * samples, as it can * from any tissue in the body. The system will be characterized with commercially available reagents and
tested on * samples to measure *, *, and gene expression.

 

ARTICLE B.2.
PRICES

 

		a.	The total fixed price of this contract is $199,833.

 

		b.	Upon delivery and acceptance of the services described in SECTION C of this contract and identified in the schedule of charges
below, the Government shall pay to the Contractor the unit price(s) set forth below:

 

	Description	 	Invoice#	 	Period Covered	 	Funded Amount	 
	PDF of Kick-off Presentation	 	HHSN261201200073C-01	 	09/28/12-10/31/12	 	$	49,958	 
	Quarterly Report 1	 	HHSN261201200073C-02	 	10/01/12-12/31/12	 	$	49,958	 
	Quarterly Report 2	 	HHSN261201200073C-03	 	01/01/13-03/31/13	 	$	49,958	 
	Draft Commercialization Plan, Draft Summary of Salient Results, Draft Final Report	 	HHSN261201200073C-04	 	09/28/12-05/31/13	 	$	24,979	 
	PDF of Final Presentation,
 Final Report, Final Summary
 of Salient Results, Final Commercialization Plan	 	HHSN261201200073C-05	 	09/28/12-06/27/13	 	$	24,980	 
	Total Fixed Price	 	 	 	 	 	$	199,833	 

 

ARTICLE B.3.
ADVANCE UNDERSTANDINGS

 

Other provisions of this contract notwithstanding, approval of the
following items within the limits set forth is hereby granted without further authorization from the Contracting Officer.

 

		a.	Indirect Costs

 

		1.	In no event shall the final amount reimbursable for Fringe Benefits exceed a ceiling of 25% of Direct Labor. In no event shall
the final amount reimbursable for General and Administrative expense exceed a ceiling of 40% of Fringe Benefits, Direct Labor,
and Total Other Direct Costs. Enumeral does not have a negotiated rate agreement in place.

 

		b.	Consultants Consultant fee to be paid to the following individual:

 

	Name	 	Rate Per Hour	 	 	Hours	 	 	Total Cost	 
	*	 	 	*	 	 	 	*	 	 	$	15,000	 

 

Award of this consulting agreement shall not proceed without
the prior written approval of the Contracting Officer.

 

    	- 4 -

    	 

    

NCI Control Number: N43CO-2012-00073

 

		c.	Contract Number Designation

 

On all correspondence submitted under this contract, the
Contractor agrees to clearly identify the two contract numbers that appear on the face page of the contract as follows:

 

Contract No. HHSN 261201200073C

 

NCI Control No.
N43C)-2012-00073

 

		d.	*

 

All * used in performance of the contract shall be de-linked
and de-identified.

 

    	- 5 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

SECTION
C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

 

ARTICLE C.1.
STATEMENT OF WORK

 

		a.	Independently and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel,
material, equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work, dated
August 15, 2012, set forth in SECTION J-List of Attachments, attached hereto and made a part of this contract.

 

ARTICLE C.2.
REPORTING REQUIREMENTS

 

All reports required herein shall be submitted in electronic format.
In addition, one hardcopy of each report shall be submitted to the Contracting Officer.

 

All electronic reports submitted shall be compliant with Section
508 of the Rehabilitation Act of 1973. Additional information about testing documents for Section 508 compliance, including specific
checklists, by application, can be found at: http://www.hhs.gov/web/508/index.html under “Helpful Resources.”

 

		a.	Technical Reports

 

In addition to those reports required by the other terms
of this contract, the Contractor shall prepare and submit the following reports in the manner stated below and in accordance with
the DELIVERIES Article in SECTION F of this contract:

 

		1.	1. Kick-off Presentation

 

The contractor shall prepare and submit a kick-off presentation.
Presentation of the slides will occur either in-person, through Webinar, or teleconference. The presentation shall cover the following:

 

a. Discussion
of company/project status, particularly changes that occurred since the proposal submission

b. Company’s
recent achievements (patents, publications, sales, regulatory approvals, partnerships, awards, etc.)

c. Status
of the field

d. Status
of commercial and academic competitors

e. Where
the proposed project is positioned against the state of the art

f. Intellectual
property landscape

g. Refresher
on the proposed technology/ R&D

h. Detailed
plan for the first budget period of the contract

i. Milestones
(technical and commercial) to be achieved by the end of the first budget period of the grant

j. Discussion
of anticipated technical risks and alternative approaches

k. Questions
to the NCI

 

		2.	Quarterly Report

 

The contractor shall submit two Quarterly Reports which
shall include:

 

a. Summary of technical objectives with status of each objective
clearly marked (e.g. Previously complete, complete during the reporting period, not started, etc.)

b. Clear description of activities accomplished in the quarter

c. Analysis of experimental data and presentation of selected
data

d. Comments regarding the timeliness of performance

 

    	- 6 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

e. Brief explanation of objectives/activities to be pursued
in the next reporting period

The report shall generally be no longer than 5 pages excluding
tables presenting the data, figures, images, and graphs.

 

		3.	Draft Commercialization Plan

 

The contractor shall submit a commercialization plan which
shall include:

 

a. Value of the SBIR/STTR Project, Expected Outcomes, and
Impact.

 

Describe, in layperson’s terms, the proposed project
and its key technology objectives. State the product, process, or service to be developed in Phase III. Clarify the need addressed,
specifying weaknesses in the current approaches to meet this need. In addition, describe the commercial applications of the research
and the innovation inherent in this application. Be sure to also specify the potential societal, educational, and scientific benefits
of this work. Explain the non-commercial impacts to the overall significance of the project. Explain how the SBIR/STTR project
integrates with the overall business plan of the company.

 

b. Organization.

 

Give a brief description of your organization including
corporate objectives, core competencies, present size (annual sales level and number and types of employees), history of previous
Federal and non-Federal funding, regulatory experience, and subsequent commercialization, and any current products/services that
have significant sales. Include a short description of the origins of the company. Indicate your vision for the future, how you
will grow/maintain a sustainable business entity, and how you will meet critical management functions as your company evolves from
a small technology R&D business to a successful commercial entity.

 

c. Market, Customer, and Competition.

 

Describe the market and/or market segments you are targeting
and provide a brief profile of the potential customer. Tell what significant advantages your innovation will bring to the market,
e.g., better performance, lower cost, faster, more efficient or effective, new capability. Explain the hurdles you will have to
overcome in order to gain market/customer acceptance of your innovation. Describe any strategic alliances, partnerships, or licensing
agreements you have in place to get FDA approval (if required) and to market and sell your product. Briefly describe your marketing
and sales strategy. Give an overview of the current competitive landscape and any potential competitors over the next several years.
(It is very important that you understand and know the competition.)

 

d. Intellectual Property (IP) Protection.

 

Describe how you are going to protect the IP that results
from your innovation. Also note other actions you may consider taking that will constitute at least a temporal barrier to others
aiming to provide a solution similar to yours.

 

e. Finance Plan.

 

Describe the necessary financing you will require to commercialize
the product, process, or service, and when it will be required. Describe your plans to raise the requisite financing to launch
your innovation into Phase III and begin the revenue stream. Plans for this financing stage may be demonstrated in one or more
of the following ways:

 

    	- 7 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

·   Letter
of commitment of funding.

·   Letter
of intent or evidence of negotiations to provide funding, should the Phase II project be successful and the market need still exist.

·   Letter
of support for the project and/or some in-kind commitment, e.g., to test or evaluate the innovation.

·   Specific
steps you are going to take to secure Phase III funding.

 

f. Production and Marketing Plan.

 

Describe how the production of your product/process/service
will occur (e.g., in-house manufacturing, contract manufacturing). Describe the steps you will take to market and sell your product/process/
service. For example, explain plans for licensing, Internet sales, etc.

 

g. Revenue Stream.

 

Explain how you plan to generate a revenue stream for your
company should this project be a success. Examples of revenue stream generation include, but are not limited to, manufacture and
direct sales, sales through value added resellers or other distributors, joint venture, licensing, service. Describe how your staffing
will change to meet your revenue expectations.

 

The Contracting Officer Representative (COR) will provide
comments regarding the Draft Commercialization Plan within ten (10) days from the receipt date of the document.

 

		4.	Draft Final Report and Draft Summary of Salient Results

 

The Draft Final Report shall consist of the work performed
and results obtained for the entire contract period of performance as stated in SECTION F of this contract. This report shall be
in sufficient detail to describe comprehensively the results achieved.

 

The Draft Summary of Salient Results shall consist of a
summary (not to exceed 200 words) of salient results achieved during the performance of the contract.

 

Both the Draft Final Report and Draft Summary of Salient
Results shall be submitted within 15 days after completing month 8 of contract performance. The COR will provide comments regarding
the Draft Final Report and Draft Summary of Salient Results within ten (10) days from the receipt date of the document.

 

		5.	Final Commercialization Plan

 

The Contractor shall provide the Final Commercialization
Plan by the completion date of the contract. This document shall include the changes required in the Draft Commercialization Plan
as well as the comments provided by the COR.

 

		6.	Final Report

 

The Contractor shall provide the Final Report by the completion
date of the contract. This document shall include the changes required in the Draft Final Report as well as the comments provided
by the COR.

 

    	- 8 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

		7.	Final Presentation

 

The contractor shall prepare and submit a final presentation.
Presentation of the slides will occur either in-person, through Webinar, or teleconference. The presentation shall cover the following:

 

a. Discussion of company/project status

b. Company’s achievements during the performance period
(patents, publications, sales, regulatory approvals, partnerships, awards, etc.)

c. Detailed results of the performed research and development

d. Discussion of proposed milestones and whether they were
achieved during the contract performance

e. Summary of submitted commercialization plan

f. If the company is interested in pursuing Phase II research,
discussion of the anticipated Phase II activities with emphasis on how they fit in the commercialization plan

g. Questions to the NCI

 

		8.	Summary of Salient Results

 

The Contractor shall submit, with the Final Report, a summary
(not to exceed 200 words) of salient results achieved during the performance of the contract.

 

		b.	Other Reports/Deliverables

 

		1.	Section 508 Annual Report

 

The contractor shall submit an annual Section 508 report
in accordance with the schedule set forth in the ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY Article in SECTION H of this
contract. The Section 508 Report Template and Instructions for completing the report are available at: http://www.hhs.gov/od
under “Vendor Information and Documents.”

 

ARTICLE C.3.
INVENTION REPORTING REQUIREMENT

 

All reports and documentation required by FAR Clause 52.227-11,
Patent Rights-Ownership by the Contractor including, but not limited to, the invention disclosure report, the confirmatory license,
and the Government support certification, shall be directed to the Division of Extramural Inventions and Technology Resources (DEITR),
OPERA, OER, NIH, 6705 Rockledge Drive, Suite 310, MSC 7980, Bethesda, Maryland 20892-7980 (Telephone: 301-435-1986). In addition,
one copy of an annual utilization report, and a copy of the final invention statement, shall be submitted to the Contracting Officer.
The final invention statement (see FAR 27.303(b)(2)(ii)) shall be submitted to the Contracting Officer on the expiration date of
the contract.

 

The annual utilization report shall be submitted in accordance with
the DELIVERIES Article in SECTION F of this contract. All reports shall be sent to the following address:

 

Heidi Crawley

Contracting Officer

NCI/OA/TSB

Office of Acquisitions

National Cancer Institute

8490 Progress Drive, Room 4045

Frederick, MD 21701-4992

 

    	- 9 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

If no invention is disclosed or no activity has occurred on a previously
disclosed invention during the applicable reporting period, a negative report shall be submitted to the Contracting Officer at
the address listed above.

 

To assist contractors in complying with invention reporting requirements
of the clause, the NIH has developed “Interagency Edison,” an electronic invention reporting system. Use of Interagency
Edison is encouraged as it streamlines the reporting process and greatly reduces paperwork. Access to the system is through a
secure interactive Web site to ensure that all information submitted is protected. Interagency Edison and information relating
to the capabilities of the system can be obtained from the Web (http;//www.iedison.gov), or by contacting the Extramural
Inventions and Technology Resources Branch, OPERA, NIH.

 

    	- 10 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

SECTION
D - PACKAGING, MARKING AND SHIPPING

 

All deliverables required under this contract shall be packaged,
marked and shipped in accordance with Government specifications. At a minimum, all deliverables shall be marked with the contract
number and Contractor name. The Contractor shall guarantee that all required materials shall be delivered in immediate usable and
acceptable condition.

 

SECTION
E - INSPECTION AND ACCEPTANCE

 

		a.	The Contracting Officer or the duly authorized representative will perform inspection and acceptance of materials and services
to be provided.

 

		b.	For the purpose of this SECTION, Contracting Officer’s Representative is the authorized representative of the Contracting
Officer.

 

		c.	Inspection and acceptance will be performed at:

 

*

National Cancer Institute

SBIR Development Center

6116 Executive Blvd.

Suite 402, MSC 8332

Bethesda, MD 20892-8332

 

Acceptance may be presumed unless otherwise indicated
in writing by the Contracting Officer or the duly authorized representative within 30 days of receipt.

 

		d.	This contract incorporates the following clause by reference, with the same force and effect as if it were given in full text.
Upon request, the Contracting Officer will make its full text available.

 

FAR Clause 52.246-7, Inspection of Research and Development
- Fixed Price (August 1996).

 

    	- 11 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

SECTION
F - DELIVERIES OR PERFORMANCE

 

ARTICLE F.1.
PERIOD OF PERFORMANCE

 

The period of performance of this contract shall be from 09/28/12
through 06/27/13.

 

ARTICLE F.2.
DELIVERIES

 

Satisfactory performance of the final contract shall be deemed to
occur upon performance of the work described in the Statement of Work Article in SECTION C of this contract and upon delivery and
acceptance by the Contracting Officer, or the duly authorized representative, of the following items in accordance with the stated
delivery schedule:

 

		a.	The items specified below as described in the REPORTING REQUIREMENTS Article in SECTION C of this contract will be required
to be delivered F.o.b. Destination as set forth in FAR 52.247-35, F.o.b. DESTINATION, WITHIN CONSIGNEES PREMISES (APRIL 1984),
and in accordance with and by the date(s) specified below:

 

	Item No.	 	Description	 	Quantity	 	Delivery Schedule
	1	 	Kick Off Presentation	 	Three (3) Copies	 	Kick-Off Presentation slides(PDF) to be delivered at the conclusion of the Kick-Off Presentation which must be completed within 60 days of contract award.
	2	 	Quarterly Report One	 	Three (3) Copies	 	01/15/2013
	3	 	Quarterly Report Two	 	Three (3) Copies	 	04/15/2013
	4	 	Draft Commercialization Plan, Draft Final Report

and Draft Summary of Salient Results	 	Three (3) Copies	 	06/15/2013
	5	 	Final Presentation, Final Summary of Salient Results, Final Report and Final Commercialization Plan	 	Three (3) Copies	 	06/27/2013
	6	 	Final Invention Statement	 	Three (3) Copies	 	06/27/2013
	7	 	Invention Disclosure Report	 	Three (3) Copies	 	06/27/2013
	8	 	Section 508 Conformance Certification	 	Two (2) Copies	 	06/27/2013

 

		b.	The above items shall be addressed and delivered to:

 

	Addressee	 	Deliverable Item No	 	Quantity
	*

Contracting Officer

*	 	Items 1-8	 	1 electronic copy
	*

Contract Specialist

*	 	Items 1-8	 	1 electronic copy
	*

Contracting Officer’s Representative

*	 	Items 1-6	 	1 electronic copy

 

    	- 12 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

	Addressee	 	Deliverable Item No	 	Quantity
	OPERA, OEH, NIH 6705

Rockledge Drive

Suite 310, MSC 7980

Bethesda, MD 20892-7980	 	Item 7	 	1 hard copy

 

		c.	Unless otherwise specified, deliveries shall be made to the Delivery Point specified above Mondays through Fridays between
the hours of 8:30a.m. and 3:30p.m. EST only. Supplies or services scheduled for delivery on a Federal Holiday or on the weekend
shall be made the following business day.

 

ARTICLE F.3.
CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)

 

This contract incorporates the following clause(s) by reference,
with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make its full text
available. Also, the full text of a clause may be accessed electronically at this address: http://www.acquisition.gov/comp/far/index.html

 

FEDERAL ACQUISITION REGULATION (48 CFR CHAPTER 1) CLAUSE:

 

52.242-15, Stop Work Order (August 1989) with Alternate
I (April 1984).

 

52.242-17, Government Delay of Work (April 1984).

 

    	- 13 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

SECTION
G - CONTRACT ADMINISTRATION DATA

 

ARTICLE G.1.
CONTRACTING OFFICER’S REPRESENTATIVE (COR)

 

The following Contracting Officer’s Representative (COR) will
represent the Government for the purpose of this contract:

 

*

 

The COR is responsible for: (1) monitoring the Contractor’s
technical progress, including the surveillance and assessment of performance and recommending to the Contracting Officer changes
in requirements; (2) interpreting the statement of work and any other technical performance requirements; (3) performing technical
evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting in the
resolution of technical problems encountered during performance.

 

The Contracting Officer is the only person with authority to act
as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct or negotiate any changes
in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule; (4) authorize
reimbursement to the Contractor for any costs incurred during the performance of this contract; or (5) otherwise change any terms
and conditions of this contract.

 

The Government may unilaterally change its COR designation.

 

ARTICLE G.2.
KEY PERSONNEL, HHSAR 352.242-70 (January 2006)

 

The key personnel specified in this contract are considered to be
essential to work performance. At least 30 days prior to diverting any of the specified individuals to other programs or contracts
(or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ of the Contractor),
the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion or replacement
request (including proposed substitutions for key personnel) to permit evaluation by the Government of the impact on performance
under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written consent of the
Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of the Contractor or
Government.

 

(End of Clause)

 

The following individual is considered to be essential to the work
being performed hereunder:

 

	Name	 	Title
	Dr. Arthur Tinkelenberg	 	Principal Investigator

 

ARTICLE G.3.
INVOICE SUBMISSION

 

		a.	Invoice Instructions for NIH Fixed-Price Type Contracts, NIH(RC)-2, are attached and made part of this contract. The Contractor
shall follow the attached instructions and submission procedures specified below to meet the requirements of a “proper invoice”
pursuant to FAR Subpart 32.9, Prompt Payment.

 

E-Mail:amy.bandel@nih.gov

 

The Contractor shall submit an electronic copy of the payment
request to the approving official instead of a paper copy. The payment request shall be transmitted as an attachment via e-mail
to the address listed above in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF). Only one
payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor’s name, contract
number, and unique invoice number.

[Note: The original payment request
must still be submitted in hard copy and mailed to the designated billing office to meet the requirements of a “proper invoice.
]

 

    	- 14 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

		1.	Payment requests shall be submitted to the offices identified below. Do not submit
supporting documentation (e.g., receipts, time sheets, vendor invoices, etc.) with your payment request unless specified elsewhere
in the contract or requested by the Contracting Officer.

 

		a.	The original invoice shall be submitted to the following
designated billing office:

 

National Institutes of Health

Office of Financial Management

Commercial Accounts

2115 East Jefferson Street, Room 4B-432, MSC 8500

Bethesda, MD 20892-8500

 

		b.	One courtesy copy of the original invoice shall be submitted
electronically as follows:

 

		1.	The Contractor shall scan the original payment request (invoice) in Adobe Portable Document Format (PDF) along with the necessary
supporting documentation as one single attachment.

 

		2.	Save the single attachment (scanned invoice along with any supporting documentation) in the following format: YourVendorName_Invoice
number (e.g., if you are submitting Invoice 123456, save the single attachment as ‘‘ABC_Company_Invoice 123456”)
[Note: Please do not use special characters such as (#, $, %,*, &, !) when saving your attachment. Only the underscore symbol
(_) is permitted.]

 

		3.	Transmit the saved single attachment via e-mail to the appropriate branch’s Central Point of Distribution as identified
in subparagraph 2.b. below. Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include
the Contract Number_ Contract Title_ Contractor’s Name_ unique Invoice number

 

(e.g, HHSN261201200068C_Clinical Genetics Support_ABC
Company_Invoice 12345) [Note: The original payment request must still be submitted in hard copy and mailed to the designated
billing office listed in subparagraph a, above, to meet the requirements of a “proper invoice.” Also, The Contractor
must certify on the payment request that the electronic courtesy copy is a duplicate of the original invoice mailed to NIH’s
Office of Financial Management.]

 

		2.	In addition to the requirements specified in FAR 32.905 for a proper invoice, the Contractor shall include the following information
on the face page of all payment requests:

 

a. Name
of the Office of Acquisitions. The Office of Acquisitions for this contract is National Cancer Institute.

 

    	- 15 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

b. Central
Point of Distribution. For the purpose of this contract, the Central Point of Distribution is NCI OA Branch C - ncibranchcinvoices@mail.nih.gov
..

 

c. Federal
Taxpayer Identification Number (TIN). If the Contractor does not have a valid TIN, it shall identify the Vendor Identification
Number (VIN) on the payment request. The VIN is the number that appears after the Contractor’s name on the face page of the
contract. [Note: A VIN is assigned to new contracts awarded on or after June 4, 2007, and any existing contract modified to
include the VIN number.] If the Contractor has neither a TIN, DUNS, or VIN, contact the Contracting Officer.

 

d. DUNS
or DUNS+4 Number. The DUNS number must identify the Contractor’s name and address exactly as stated in the contract and as
registered in the Central Contractor Registration (CCR) database. If the Contractor does not have a valid DUNS number, it shall
identify the Vendor Identification Number (VIN) on the payment request. The VIN is the number that appears after the Contractor’s
name on the face page of the contract. [Note: A VIN is assigned to new contracts awarded on or after June 4, 2007, and any existing
contract modified to include the VIN number.] If the Contractor has neither a TIN, DUNS, or VIN, contact the Contracting Officer.

 

e. Invoice
Matching Option. This contract requires a two-way match.

 

f. Unique
Invoice Number. Each payment request must be identified by a unique invoice number, which can only be used one time regardless
of the number of contracts or orders held by an organization.

 

g. Contract
Title: The contract title, located in block 15B of the first page of the contract document, shall be placed on all invoices submitted
for payment.

 

		b.	Inquiries regarding payment of invoices shall be directed to the designated billing office, (301) 496-6452.

 

    	- 16 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

ARTICLE G.4.
POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE

 

		a.	Contractor Performance Evaluations

 

Interim and final evaluations of Contractor performance
will be prepared on this contract in accordance with FAR Subpart 42.15. The final performance evaluation will be prepared at the
time of completion of work.

 

Interim and final evaluations will be provided to the
Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review the
document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties, the
matter will be referred to an individual one level above the Contracting Officer, whose decision will be final.

 

Copies of the evaluations, Contractor responses, and review
comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.

 

		b.	Electronic Access to Contractor Performance Evaluations

 

Contractors may access evaluations through a secure Web
site for review and comment at the following address:

 

http://www.cpars.gov

 

    	- 17 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

SECTION
H - SPECIAL CONTRACT REQUIREMENTS

 

ARTICLE H.1.
HUMAN SUBJECTS

 

It is hereby understood and agreed that research involving human
subjects shall not be conducted under this contract, and that no material developed, modified, or delivered by or to the Government
under this contract, or any subsequent modification of such material, will be used by the Contractor or made available by the Contractor
for use by anyone other than the Government, for experimental or therapeutic use involving humans without the prior written approval
of the Contracting Officer.

 

ARTICLE H.2.
HUMAN MATERIALS

 

The acquisition and supply of all human specimen material (including
fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable State and Local
laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise,
will be offered to any person to influence their donation of human material.

 

ARTICLE H.3.
HUMAN MATERIALS (ASSURANCE OF OHRP COMPLIANCE)

 

The acquisition and supply of all human specimen material (including
fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable State and Local
laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary or otherwise,
will be offered to any person to influence their donation of human material.

 

The Contractor shall provide written documentation that all human
materials obtained as a result of research involving human subjects conducted under this contract, by collaborating sites, or by
subcontractors identified under this contract, were obtained with prior approval by the Office for Human Research Protections (OHRP)
of an Assurance to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction applies to all
collaborating sites without OHRP-approved Assurances, whether domestic or foreign, and compliance must be ensured by the Contractor.

 

Provision by the Contractor to the Contracting Officer of a properly
completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form
OMB No. 0990-0263(formerly Optional Form 310), certifying IRB review and approval of the protocol from which the human materials
were obtained constitutes the written documentation required. The human subject certification can be met by submission of a self
designated form, provided that it contains the information required by the “Protection of Human Subjects Assurance Identification/IRB
Certification/Declaration of Exemption”, Form OMB No. 0990-0263(formerly Optional Form 310).

 

ARTICLE H.4.
NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH

 

NIH-funded investigators shall submit to the NIH National Library
of Medicine’s (NLM) PubMed Central (PMC) an electronic version of the author’s final manuscript, upon acceptance for
publication, resulting from research supported in whole or in part with direct costs from NIH. NIH defines the author’s
final manuscript as the final version accepted for journal publication, and includes all modifications from the publishing peer
review process. The PMC archive will preserve permanently these manuscripts for use by the public, health care providers, educators,
scientists, and NIH. The Policy directs electronic submissions to the NIH/NLM/PMC: http://www.pubmedcentral.nih.gov.

 

Additional information is available at http://grants.nih.gov/grants/guide/notice-files/NOT-OD-08-033.html.

 

    	- 18 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

ARTICLE H.5.
NEEDLE DISTRIBUTION

 

The Contractor shall not use contract funds to carry out any program
of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

 

ARTICLE H.6.
ACKNOWLEDGEMENT OF FEDERAL FUNDING

 

The Contractor shall clearly state, when issuing statements, press
releases, requests for proposals, bid solicitations and other documents describing projects or programs funded in whole or in part
with Federal money: (1) the percentage of the total costs of the program or project which will be financed with Federal money;
(2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount of the total costs
of the project or program that will be financed by nongovernmental sources.

 

ARTICLE H.7.
CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH

 

The Contractor shall not use contract funds for (1) the creation
of a human embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are destroyed, discarded,
or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero under 45 CFR 46.204(b)
and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). The term “human embryo or embryos” includes
any organism, not protected as a human subject under 45 CFR 46 as of the date of the enactment of this Act, that is derived
by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid cells.

 

Additionally, in accordance with a March 4, 1997 Presidential Memorandum,
Federal funds may not be used for cloning of human beings.

 

ARTICLE H.8.
DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION

 

The Contractor shall not use contract funds to disseminate information
that is deliberately false or misleading.

 

ARTICLE H.9.
LIMITATIONS ON SUBCONTRACTING - SBIR

 

The Contractor shall perform a minimum of two-thirds of the research
and/or analytical effort (total contract price less profit/fee) conducted under this contract. Any deviation from this requirement
must be approved in writing by the Contracting Officer.

 

ARTICLE H.10.
ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY, HHSAR 352.239-73(b) (January 2010)

 

		a.	Pursuant to Section 508
                                         of the Rehabilitation Act of 1973 (29 U.S.C. 794d), as amended by the Workforce Investment
                                         Act of 1998, all electronic and information technology (EIT) products and services developed,
                                         acquired, maintained, or used under this contract/order must comply with the “Electronic
                                         and Information Technology Accessibility Provisions” set forth by the Architectural
                                         and Transportation Barriers Compliance Board (also referred to as the “Access Board”)
                                         in 36 CFR part 1194. Information about Section 508 provisions is available at http://www.section508.gov/.
                                         The complete text of Section 508 Final provisions can be accessed at

                                         http://www.access-board.gov/sec508/provisions.htm.

 

		b.	The Section 508 standards applicable to this contract/order are identified in the Statement of Work. The contractor must provide
a written Section 508 conformance certification due at the end of each contract/order exceeding $100,000 when the contract/order
duration is one year or less. If it is determined by the Government that
EIT products and services provided by the Contractor do not conform to the described accessibility standards in the Product Assessment
Template, remediation of the products or services to the level of conformance specified in the Contractor’s Product Assessment
Template will be the responsibility of the Contractor at its own expense.

 

    	- 19 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

		c.	In the event of a modification(s)
                                         to this contract/order, which adds new EIT products or services or revises the type of,
                                         or specifications for, products or services the Contractor is to provide, including EIT
                                         deliverables such as electronic documents and reports, the Contracting Officer may require
                                         that the contractor submit a completed HHS Section 508 Product Assessment Template to
                                         assist the Government in determining that the EIT products or services support Section
                                         508 accessibility standards. Instructions for documenting accessibility via the HHS Section
                                         508 Product Assessment Template may be found under Section 508 policy on the HHS Office
                                         on Disability Web site (http://www.hhs.gov/od/)

 

ARTICLE H.11.
PUBLICATION AND PUBLICITY

 

In addition to the requirements set forth in HHSAR Clause 352.227-70,
Publications and Publicity incorporated by reference in SECTION I of this contract, the Contractor shall acknowledge the support
of the National Institutes of Health whenever publicizing the work under this contract in any media by including an acknowledgment
substantially as follows:

 

“This project has been funded
in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health
and Human Services, under Contract No. HHSN261201200068Cn

 

ARTICLE H.12.
REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

 

Anyone who becomes aware of the existence or apparent existence
of fraud, waste and abuse in NIH funded programs is encouraged to report such matters to the HHS Inspector General’s Office
in writing or on the Inspector General’s Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477). All telephone
calls will be handled confidentially. The e-mail address is Htips@os.dhhs.gov and the mailing address is:

 

Office of Inspector General

Department of Health and Human Services

TIPS HOTLINE

P.O. Box 23489

Washington, D.C. 20026

 

ARTICLE H.13.
YEAR 2000 COMPLIANCE

 

In accordance with FAR 39.106, Information Technology acquired under
this contract must be Year 2000 compliant as set forth in the following clause(s):

 

		1.	Service Involving the Use of Information Technology

YEAR 2000 COMPLIANCE—SERVICE INVOLVING THE USE OF INFORMATION TECHNOLOGY

 

The Contractor agrees that each item of hardware, software,
and firmware used under this contract shall be able to accurately process date data (including, but not limited to, calculating,
comparing and sequencing) from, into and between the twentieth and twenty-first centuries and the Year 1999 and the Year 2000 and
leap year calculations.

 

(End of Clause)

 

    	- 20 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

PART II - CONTRACT
CLAUSES

 

SECTION
I - CONTRACT CLAUSES

 

ARTICLE I.1.
GENERAL CLAUSES FOR A FIXED-PRICE RESEARCH AND DEVELOPMENT SBIR PHASE I CONTRACT

 

This contract incorporates the following clauses by
reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer will make
their full text available. Also, the full text of a clause may be accessed electronically as follows: FAR Clauses at: https://www.acquisition.gov/far/.
HHSAR Clauses at: http://www.hhs.gov/policies/hhsar/subpart352.html.

 

		a.	FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

 

	
        FAR

        CLAUSE NO.
	 	DATE	 	TITLE
	52.202-1	 	Jan 2012	 	Definitions (Over the Simplified Acquisition Threshold)
	52.203-12	 	Oct 2010	 	Limitation on Payments to Influence Certain Federal Transactions (Over $150,000)
	52.204-7	 	Aug 2012	 	Central Contractor Registration
	52.204-10	 	Aug 2012	 	Reporting Executive Compensation and First-Tier Subcontract Awards ($25,000 or more)
	52.209-6	 	Dec 2010	 	Protecting the Government’s Interests When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment (Over $30,000)
	52.215-8	 	Oct 1997	 	Order of Precedence - Uniform Contract Format
	52.219-6	 	Jut 1996	 	Notice of Total Small Business Set-Aside
	52.222-3	 	Jun 2003	 	Convict Labor
	52.222-21	 	Feb 1999	 	Prohibition of Segregated Facilities
	52.222-26	 	Mar 2007	 	Equal Opportunity
	52.222-35	 	Sep 2010	 	Equal Opportunity for Veterans ($100,000 or more)
	52.222-36	 	Oct 2010	 	Affirmative Action for Workers with Disabilities
	52.222-37	 	Sep 2010	 	Employment Reports on Veterans ($100,000 or more)
	52.222-50	 	Feb 2009	 	Combating Trafficking in Persons
	52.222-54	 	Jut 2012	 	Employment Eligibility Verification (Over the Simplified Acquisition Threshold)
	52.223-6	 	May 2001	 	Drug-Free Workplace
	52.223-18	 	Aug 2011	 	Encouraging Contractor Policies to Ban Text Messaging While Driving
	52.225-1	 	Feb 2009	 	Buy American Act - Supplies
	52.225-13	 	Jun 2008	 	Restrictions on Certain Foreign Purchases
	52.227-1	 	Dec 2007	 	Authorization and Consent, Alternate I (Apr 1984)

 

    	- 21 -

    	 

    

NCI Control Number: N43CO-2012-00073

 

	
        FAR

        CLAUSE NO.
	 	DATE	 	TITLE
	52.227-2	 	Dec 2007	 	Notice and Assistance Regarding Patent and Copyright Infringement
	52.227-11	 	Dec 2007	 	Patent Rights - Ownership by the Contractor (Note: In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv). The frequency of reporting in (i) is annual.
	52.227-20	 	Dec 2007	 	Rights in Data - SBIR Program
	52.232-9	 	Apr 1984	 	Limitation on Withholding of Payments
	52.232-23	 	Jan 1986	 	Assignment of Claims
	52.232-25	 	Oct 2008	 	Prompt Payment
	52.232-33	 	Oct 2003	 	Payment by Electronic Funds Transfer-Central Contractor Registration
	52.233-1	 	Jul 2002	 	Disputes
	52.233-3	 	Aug 1996	 	Protest After Award
	52.233-4	 	Oct 2004	 	Applicable Law for Breach of Contract Claim
	52.243-1	 	Aug 1987	 	Changes - Fixed Price, Alternate V (Apr 1984)
	52.244-6	 	Dec 2010	 	Subcontracts for Commercial Items
	52.249-1	 	Apr 1984	 	Termination for the Convenience of the Government (Fixed-Price) (Short Form)
	52.249-9	 	Apr 1984	 	Default (Fixed-Price Research and Development) (Over the Simplified Acquisition Threshold)
	52.249-14	 	Apr 1984	 	Excusable Delays
	52.253-1	 	Jan 1991	 	Computer Generated Forms

 

		b.	DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER
3) CLAUSES:

 

	
        HHSAR

        CLAUSE NO.
	 	DATE	 	TITLE
	352.202-1	 	Jan 2006	 	Definitions
	352.203-70	 	Mar 2012	 	Anti-Lobbying
	352.222-70	 	Jan 2010	 	Contractor Cooperation in Equal Employment Opportunity Investigations
	352.227-70	 	Jan 2006	 	Publications and Publicity
	352.231-71	 	Jan 2001	 	Pricing of Adjustments
	352.242-70	 	Jan 2006	 	Key Personnel
	352.242-73	 	Jan 2006	 	Withholding of Contract Payments

 

[End of GENERAL CLAUSES FOR A FIXED-PRICE RESEARCH AND DEVELOPMENT
SBIR PHASE I CONTRACT- Rev. 08/2012].

    	- 22 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

ARTICLE I.2.
AUTHORIZED SUBSTITUTION OF CLAUSES

 

ARTICLE I.1. of this SECTION is hereby modified as follows:

 

		a.	Alternate IV (October 2010) of FAR Clause 52.215-21, Requirements for Certified Cost
or Pricing Data and Data Other Than Certified Cost or Pricing Data—Modifications (October
2010) is added.

 

    	- 23 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

ARTICLE I.3.
Additional Contract Clauses

 

This contract incorporates the following clauses by reference, with
the same force and effect, as if they were given in full text. Upon request, the Contracting Officer will make their full text
available.

 

		a.	FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES

 

		1.	FAR Clause 52.219-28, Post-Award Small Business Program Rerepresentation (April 2012).

 

		2.	FAR Clause 52.227-16, Additional Data Requirements (June 1987).

 

		3.	FAR Clause 52.244-5, Competition in Subcontracting (December 1996).

 

		4.	FAR Clause 52.246-23, Limitation of Liability (February 1997).

 

		b.	DEPARTMENT OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CHAPTER 3) CLAUSES:

 

		1.	THERE ARE NO APPLICABLE CLAUSES IN THIS SECTION.

 

		c.	NATIONAL INSTITUTES OF HEALTH (NIH) RESEARCH CONTRACTING (RC) CLAUSES:

 

The following clauses are attached and made a part of this contract:

 

		1.	THERE ARE NO APPLICABLE CLAUSES IN THIS SECTION.

 

    	- 24 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

ARTICLE I.4.
ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

 

This contract incorporates the following clauses in full text.

 

		a.	THERE ARE NO APPLICABLE CLAUSES IN THIS SECTION.

 

    	- 25 -

    	 

    

 

NCI Control Number: N43CO-2012-00073

 

PART III - LIST
OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

 

SECTION
J - LIST OF ATTACHMENTS

 

The following documents are attached and incorporated in this contract:

 

1. Statement of Work

 

Statement of Work, dated August 15, 2012, 2 pages.

 

2. Invoice Instructions for NIH Fixed-Price Contracts, NIH(RC)-2

 

Invoice Instructions for NIH Fixed-Price Contracts, NIH(RC)-2, (8/12),
3 pages.

 

3. Safety and Health

 

Safety and Health, HHSAR Clause 352.223-70, (1/06), 2 pages.

 

4. Disclosure of Lobbying Activities, SF-LLL

 

Disclosure of Lobbying Activities,
SF-LLL, dated 7/97, 2 pages.

 

    	- 26 -

    	 

    

 

STATEMENT OF WORK (Phase I)

 

	TITLE:	*
	PRINCIPAL INVESTIGATOR(S):	Dr. Arthur Tinkelenberg
	PROJECT DURATION:	9 months
	COMPANY:	Enumeral Biomedical Corp
	SUBCONTRACTORS:	NA

 

		I.	Background Information and Objectives

 

		A.	Background Information

Cancer is a leading cause of death that affects millions of lives
across the world. It is a complex disease that is likely to require multifactorial measurements for earlier and more accurate diagnosis
and patient stratification. Tissue biopsies and fine needle aspirates are commonly collected clinically, but existing multi-analyte
technology platforms are ill-equipped to derive meaningful information from single samples.

 

The goal of this proposal is to characterize Enumeral’s
technology for the * on clinical samples and to * to be used in Phase II. Enumeral’s platform is ideally suited for the measurement
of * samples, as it can * from any tissue. The system will be characterized with commercially available reagents and tested on
* samples to measure *, *, and gene expression.

 

With the mortality associated with cancer and the sheer volume of
clinical samples taken on an annual basis, the advancement of technologies for the analysis of * samples has the potential to advance
the understanding of cancer progression and open new doors for diagnostic and treatment paradigms.

 

		B.	Technical Objectives

Objective #1: Assay Development. Design and characterize an assay
using Enumeral’s technology to measure a wide range of * samples.

 

Milestone 1.1 – Design assay and validate *.
* can be validated by confirming lack of * between * on the * and *, specifically, * should show a *.

 

Milestone 1.2 - Characterize assay sensitivity and
repeatability for *. Confirm via * that the * for each * and that the * as measured by * is *.

 

Milestone 1.3 - Establish protocol for *. Milestone
is complete when * and *.

 

Objective #2: Data Collection & Analysis. Characterize the
process and performance of Enumeral’s technology using *.

 

For the characterization of the assay, we have used * of the *,
as this allows *, focusing instead on *. This should allow for * and be largely independent of the assay itself.

 

Milestone 2.1 - Characterize the * and * and/or * in
*.

 

2.1(A) The number of * should be *. The level of * should
serve as *.

 

2.1(B) for *, the number of * is expected to vary from
sample to sample. The * should be within *.

 

2.1(C) for * as above, the * should be within *.

 

Objective #3: Design *. Develop a * that will allow construction
and testing in Phase II.

 

Milestone 3.1 - Conduct procedural analysis of microengraving
process. Identify any * that will * and *. Identify areas where the * can be achieved in an *, with the goal of *.

 

Attachment 1

 

    	 

    	 

    

Milestone 3.2 - Design * that includes * and *.
This * should reflect * and * and should *.

 

Milestone 3.3 - Perform * to identify areas where *
for a *. Produce * that are required for * and for which there is presently *. Produce * that will lead to * in a * by * when
compared to *.

 

		II.	Services to be Performed

 

		A.	General Requirements

 

		1.	The contractor shall independently perform all work and furnish all labor, materials, supplies, equipment, and services (except
as otherwise specified in the contract).

 

		2.	All work will be monitored by the Government Project Officer identified in Section G of the contract.

 

		B.	Specific Requirements

 

Phase I Milestones and Timeline

(Please feel free to use format appropriate
for your project)

 

	 	 	 	 	
        Months

        1-3
	 	Months

4-6	 	
        Months

        7-9

	Objective #1:  Assay Development.	 	Milestone 1.1 – Design assay and order *.	 	Month 1	 	 	 	 
	 	 	Milestone 1.2 - Characterize assay *	 	Month 3	 	 	 	 
	 	 	Milestone 1.3 - Establish *	 	Month 3	 	 	 	 
	Objective #2:  Data Collection & Analysis.	 	Milestone 2.1 - Characterize the * and *.	 	 	 	(Ongoing)	 	Month 7
	Objective #3:  Design Automation Prototype.	 	Milestone 3.1 - Conduct procedural analysis of microengraving process	 	 	 	 	 	Month 8
	 	 	Milestone 3.2 - Design * that includes * and identifies*	 	 	 	 	 	Month 8
	 	 	Milestone 3.3 - Perform * to * where *.	 	 	 	 	 	Month 8
	Deliver Final Report to NCI	 	 	 	 	 	 	 	Month 9

 

    	 

    	 

    

 

 

FOIA CONFIDENTIAL TREATMENT REQUESTED BY
ENUMERAL BIOMEDICAL HOLDINGS, INC.

 

    	 

    	 

    

 

Invoice instructions
for NIH Fixed-price contracts, nih(rc)-2

 

Format: Submit payment requests on Standard Form 1034, Public
Voucher for Purchases and Services Other Than Personal, or the Contractor’s self-generated form provided it contains all
of the information prescribed herein. DO NOT include a cover letter with the payment request.

 

Number of Copies: Submit payment requests in the quantity
specified in the Invoice Submission Instructions in Section G of the Contract Schedule.

 

Frequency: Submit payment requests upon delivery and acceptance
of goods or services unless otherwise authorized by the Contracting Officer.

 

Preparation and Itemization of the Payment Request: Prepare
payment requests as follows:

 

Note: All information must
be legible or the invoice will be considered improper and returned to the Contractor.

 

		(a)	Designated Billing Office Name and Address: Enter the designated billing office name and address, as identified in the
Invoice Submission Instructions in Section G of the Contract Schedule.

 

		(b)	Contractor’s Name, Address, Point of Contact, TIN, and DUNS or DUNS+4 Number: Show the Contractor’s name
and address exactly as they appear in the contract. Any invoice identified as improper will be sent to this address. Also include
the name, title, phone number, and e-mail address of the Point of Contact in case of questions. If the remittance name differs
from the legal business name, both names must appear on the invoice. Provide the Contractor’s Federal Taxpayer Identification
Number (TIN) and Data Universal Numbering System (DUNS) or DUNS+4 number. The DUNS number must identify the Contractor’s
name and address exactly as stated in the contract, and as registered in the Central Contractor Registration (CCR) database.

 

When an approved assignment of claims has been executed,
the Contractor shall provide the same information for the assignee as is required for the Contractor (i.e., name, address, point
of contact, TIN, and DUNS number), with the remittance information clearly identified as such.

 

		(c)	Invoice/Voucher Number: Identify each payment request by a unique invoice number, which can only be used one time regardless
of the number of contracts or orders held by an organization. For example, if a contractor has already submitted invoice number
05 on one of its contracts or orders, it cannot use that same invoice number on any other contract or order. Payment requests with
duplicate invoice numbers will be considered improper and returned to the contractor.

 

The NIH does not prescribe a particular numbering format
but suggests using a job or account number for each contract and order followed by a sequential invoice number (example: 8675309-05).
Invoice numbers are limited to 30 characters. There are no restrictions on the use of special characters, such as colons, dashes,
forward slashes, or parentheses.

 

If all or part of an invoice is suspended and the contractor
chooses to reclaim those costs on a supplemental invoice, the contractor may use the same unique invoice number followed by an
alpha character, such as “R” for revised (example: 8675309-05R).

 

		(d)	Date Invoice/Voucher Prepared: Insert the date the payment request is prepared.

 

		(e)	Contract Number and Order Number (if applicable): Insert the contract number and order number (if applicable).

 

		(f)	Contract Title: Insert the contract title listed on the cover page of the contract.

 

	NIH(RC)-2	Attachment 2
	8/2012	 

 

    	1

    	 

    

		(g)	Current Contract Period of Performance: Insert the contract start date/effective date through the current completion
date of the contract.

 

		(h)	Effective Date: Insert the effective date of the contract or if billing under an order, the effective date of the order.

 

		(i)	Total Fixed-Price of Contract/Order: Insert the total fixed-price of the contract/order.

 

		(j)	Two-Way/Three-Way Match: Identify whether payment is to be made using a two-way or three-way match. To determine required
payment method, refer to the Invoice Submission Instructions in Section G of the Contract Schedule.

 

		(k)	Office of Acquisitions: Insert the name of the Office of Acquisitions, as identified in the Invoice Submission Instructions
in Section G of the Contract Schedule.

 

		(l)	Central Point of Distribution: Identify the Central Point of Distribution, as specified in the Invoice Submission Instructions
in Section G of the Contract Schedule.

 

		(m)	Billing Period: Insert the beginning and ending dates (month, day, and year) of the period in which costs were incurred
and for which reimbursement is claimed.

 

		(n)	Description of Supplies or Services: Provide a description of the supplies or services; by line item (if applicable),
quantity, unit price (where appropriate), and total amount. The item description, unit of measure, and unit price must match
those specified in the contract. For example, if the contract specifies 1 box of hypodermic needles (100/box) with a unit price
of $50.00, then the invoice must state 1 box, hypodermic needles (100/box), $50.00, not 100 syringes at $0.50 each.
Invoices that do not match the line item pricing in the contract will be considered improper and will be returned to the Contractor.

 

		(o)	Amount Billed - Current Period: Insert the amount claimed for the current billing period, including any adjustments,
if applicable. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment
request.

 

		(p)	Amount Billed - Cumulative: Insert the cumulative amounts claimed to date, including any adjustments as applicable.
If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request.

 

		(q)	Freight or Delivery Charges: Identify all charges for freight or express shipments, other than f.o.b. destination, as
a separate line item on the invoice. (If shipped by freight or express, and charges are more than $25, attach prepaid bill.)

 

		(r)	Government Property: If the contract authorizes the purchase of any item of Government Property (e.g., equipment), the
invoice must list each item for which reimbursement is requested. Include reference to the following (as applicable):

 

		-	item number for the specific piece of equipment listed in the Property Schedule, and

		-	Contracting Officer Authorization (COA) Number, if the equipment is not covered by the Property Schedule.

 

Currency: All NIH contracts are expressed in United States
dollars. When the Government pays in a currency other than United States dollars, billings shall be expressed, and payment by the
Government shall be made, in that other currency at amounts coincident with actual costs incurred. Currency fluctuations may not
be a basis of gain or loss to the Contractor. Notwithstanding the above, the total of all invoices paid under this contract may
not exceed the United States dollars authorized.

 

	NIH(RC)-2	Attachment 2
	8/2012	 

 

    	2

    	 

    

 

 

    	 

    	 

    

 

Safety and Health, HHSAR 352.223-70 (January
2006)

 

		(a)	To help ensure the protection of the life and health of all persons, and to help prevent damage to property, the Contractor
shall comply with all Federal, State, and local laws and regulations applicable to the work being performed under this contract.
These laws are implemented or enforced by the Environmental Protection Agency, Occupational Safety and Health Administration (OSHA)
and other regulatory/enforcement agencies at the Federal, State, and local levels.

 

		(1)	In addition, the Contractor shall comply with the following regulations when developing and implementing health and safety
operating procedures and practices for both personnel and facilities involving the use or handling of hazardous materials and the
conduct of research, development, or test projects:

 

		(ii)	29 CFR 1910.1030, Bloodborne pathogens; 29 CFR 1910.1450, Occupational
                                         exposure to hazardous chemicals in laboratories; and other applicable occupational health
                                         and safety standards issued by OSHA and included in 29 CFR Part 1910. These regulations
                                         are available at: http://www.osha.gov.

 

		(ii)	Nuclear Regulatory Commission Standards and Regulations, pursuant to the Energy Reorganization Act of 1974 (42 U.S.C. 5801
et seq.). The Contractor may obtain copies from the U.S. Nuclear Regulatory Commission, Washington, DC 20555- 0001.

 

		(2)	The following Government guidelines are recommended for developing and implementing health and safety operating procedures
and practices for both personnel and facilities:

 

		(i)	Biosafety in Microbiological and Biomedical Laboratories, CDC.
                                         This publication is available at http://www.cdc.gov/OD/ohs/biosfty/bmbl4/bmbl4toc.htm.

 

		(ii)	Prudent Practices for Safety in Laboratories (1995), National
                                         Research Council, National Academy Press, 500 Fifth Street, NW., Lockbox 285, Washington,
                                         DC 20055 (ISBN 0-309-05229-7). This publication is available at http://www.nap.edu/catalog/4911.html.

 

		(b)	Further, the Contractor shall take or cause to be taken additional safety measures as the Contracting Officer, in conjunction
with the Contracting Officer’s Technical Representative or other appropriate officials, determines to be reasonably necessary.
If compliance with these additional safety measures results in an increase or decrease in the cost or time required for performance
of any part of work under this contract, the Contracting Officer will make an equitable adjustment in accordance with the applicable
“Changes” clause set forth in this contract.

 

		(c)	The Contractor shall maintain an accurate record of, and promptly report to the Contracting Officer, all accidents or incidents
resulting in the exposure of persons to toxic substances, hazardous materials or hazardous operations; the injury or death of any
person; or damage to property incidental to work performed under the contract and all violations for which the Contractor has been
cited by any Federal, State or local regulatory/enforcement agency. The report shall include a copy of the notice of violation
and the findings of any inquiry or inspection, and an analysis addressing the impact these violations may have on the work remaining
to be performed. The report shall also state the required action(s), if any, to be taken to correct any violation(s) noted by the
Federal, State or local regulatory/enforcement agency and the time frame allowed by the agency to accomplish the necessary corrective
action.

 

Safety and Health, HHSAR 352.223-70 (January 2006)

Attachment 3 

    	Page 1 of 2

    	 

    

		(d)	If the Contractor fails or refuses to comply with the Federal, State or local regulatory/enforcement agency’s directive(s)
regarding any violation(s) and prescribed corrective action(s), the Contracting Officer may issue an order stopping all or part
of the work until satisfactory corrective action (as approved by the Federal, State or local regulatory/enforcement agencies) has
been taken and documented to the Contracting Officer. No part of the time lost due to any stop work order shall be subject to a
claim for extension of time or costs or damages by the Contractor.

 

		(e)	The Contractor shall insert the substance of this clause in each subcontract involving toxic substances, hazardous materials,
or hazardous operations. The Contractor is responsible for the compliance of its subcontractors with the provisions of this clause.

 

(End of clause)

 

Safety and Health, HHSAR 352.223-70 (January 2006)

    	Page 2 of 2

    	 

    

 

 

Attachment 4

    	 

    	 

    

 

INSTRUCTIONS FOR COMPLETION OF SF-LLL,
DISCLOSURE OF LOBBYING ACTIVITIES

 

This disclosure form shall be completed by
the reporting entity, whether subawardee or prime Federal recipient, at the initiation or receipt of a covered Federal action,
or a material change to a previous filing, pursuant to title 31 U.S.C. section 1352. The filing of a form is required for each
payment or agreement to make payment to any lobbying entity for influencing or attempting to influence an officer or employee of
any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection with
a covered Federal action. Complete all items that apply for both the initial filing and material change report. Refer to the implementing
guidance published by the Office of Management and Budget for additional information.

 

		1.	Identify the type of covered Federal action for which lobbying activity is and/or has been secured to influence the outcome
of a covered Federal action.

 

		2.	Identify the status of the covered Federal action.

 

		3.	Identify the appropriate classification of this report. If this is a followup report caused by a material change to the information
previously reported, enter the year and quarter in which the change occurred. Enter the date of the last previously submitted report
by this reporting entity for this covered Federal action.

 

		4.	Enter the full name, address, city, State and zip code of the reporting entity. Include Congressional District, if known. Check
the appropriate classification of the reporting entity that designates if it is, or experts to be. a prime or subaward recipient.
Identify the tier of the subawardee, e.g., the first subawardee of the prime is the 1st tier. Subawards include but are not limited
to subcontracts, subgrants and contract awards under grants.

 

		5.	If the organization filing the report in item 4 checks “Subawardee,” then enter the full name, address, city, State
and zip code of the prime Federal recipient. Include Congressional District, if known.

 

		6.	Enter the name of the Federal agency making the award or loan commitment. Include at least one organizational level below agency
name, if known. For example. Department of Transportation, United States Coast Guard.

 

		7.	Enter the Federal program name or description for the covered Federal action (item 1). If known, enter the full Catalog of
Federal Domestic Assistance (CFDA) number for grants, cooperative agreements, loans, and loan commitments.

 

		8.	Enter the most appropriate Federal identifying number available for the Federal action identified in item 1 (e.g., Request
for Proposal (RFP) number; Invitation for Bid (IFB) number; grant announcement number; the contract, grant, or loan award number;
the application/proposal control number assigned by the Federal agency). Include prefixes, e.g., “RFP-OE-90-001.”

 

		9.	For a covered Federal action where there has been an award or loan commitment by the Federal agency, enter the Federal amount
of the award/loan commitment for the prime entity identified in item 4 or 5.

 

		10.	(a)  Enter the full name, address, city, State and
zip code of the lobbying registrant under the Lobbying Disclosure Act of 1995 engaged by the reporting entity identified in item
4 to influence the covered Federal action.

 

			(b)   Enter the full names of the individual(s) performing
services, and include full address if different from 10 (a). Enter Last Name, First Name, and Middle Initial (Ml).

 

		11.	The certifying official shall sign and date the form, print his/her name, title, and telephone number.

 

	According to the Paperwork Reduction Act, as amended, no persons are required to respond to a collection of information unless it displays a valid OMB Control Number. The valid OMB control number for this information collection is OMB No. 0348-0046. Public reporting burden for this collection of information is estimated to average 10 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management and Budget, Paperwork Reduction Project (0348-0046), Washington, DC 20503. 

 

    	 

    	 

    

 

Contract Number : HHSN261201200073C

NCI Control Number : N43CO-2012-00073

 

PART IV - REPRESENTATIONS
AND INSTRUCTIONS

 

SECTION
K - REPRESENTATIONS AND CERTIFICATIONS

 

The following documents are incorporated by reference to this contract:

 

		1.	Annual Representations and Certifications completed and located at the Online Representations and Certifications Application
(ORCA) at the System for Acquisition Management (SAM) website (www.sam.gov)

 

		2.	NIH Representations & Certifications, dated 08/02/2012

 

FOIA CONFIDENTIAL TREATMENT REQUESTED BY ENUMERAL BIOMEDICAL
HOLDINGS, INC.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]